glp-1 dual agonist Frontiers Trends in the Development of

This can be achieved through dietary stimulants, pharmacological agents, or interventions targeting the gut microbiota

This phenomenon is further illustrated by results from a randomized, open-label mechanistic trial in patients with T2DM, which demonstrated that lixisenatide, with a half-life of 2 4 hours, had a significantly greater effect than liraglutide in delaying in gastric emptying and curtailing postprandial glucose excursions following a standardized solid breakfast (156)

[DOI] [PMC free article] [PubMed] [Google Scholar] 709.McCrimmon R.J., Fan X., Ding Y., Zhu W., Jacob R.J., Sherwin R.S

Black circle added to the green indicates that these synthetic agonists have been slightly modified

Microbial enterotypes and weight loss: results from a randomized controlled trial

Mol Metab 2014;4:118-31.ArticlePubMedPMC 89